Introduction
Early in the COVID-19 pandemic, clinical research focused heavily on hospitalized patients, leaving a significant gap in our understanding of the factors that influence initial susceptibility to SARS-CoV-2. Furthermore, many early studies relied on standardized registries that lacked the granular medical histories necessary to identify subtle risk factors.
This study addresses these gaps by analyzing the full spectrum of the disease—from initial susceptibility (testing positive) to inpatient admission and severe outcomes (ICU treatment or intubation). By leveraging the diverse patient population of the UCLA Health System in Los Angeles, researchers sought to identify how prior diagnoses, medications, and demographic factors contribute to COVID-19 risk and the disproportionate impact of the virus on minority communities.
Methodology
The researchers conducted a retrospective case-control study using de-identified electronic health records (EHR) from the UCLA Data Discovery Repository (DDR). The cohort included 26,602 individuals tested for SARS-CoV-2 via PCR between March 9 and June 14, 2020. Of these, 992 tested positive, 220 were admitted to the hospital, and 77 experienced severe outcomes.
To manage the complexity of thousands of individual ICD-9/10 diagnosis codes, the team mapped them to approximately 1,800 "phecodes"—clinically meaningful groupings of phenotypes. They employed Firth logistic regression, a statistical method optimized for "rare events" in medical data, to analyze three distinct tiers:
- Susceptibility: Comparing COVID-19 positive patients against an age- and sex-matched sample from the general health system.
- Admission: Comparing hospitalized patients against non-hospitalized positive patients.
- Severity: Comparing ICU/intubated patients against non-severe hospitalized patients.
Demographic Disparities
The study confirmed that males and individuals over the age of 65 faced an increased risk of hospital admission. However, a notable trend emerged regarding age and severity: once admitted, the intermediate age group (26–55) showed a higher risk of progressing to severe outcomes compared to the >65 group.
One of the most striking findings was the "Hispanic/Latino Disparity." Individuals self-identifying as Hispanic or Latino constituted 24% of those testing positive but 40% of those with severe outcomes. Crucially, this disparity persisted even after correcting for medical comorbidities. This suggests that non-medical factors—such as housing density, frontline work environments, or socioeconomic barriers—played a dominant role in disease progression for this community.
Clinical Predictors of Susceptibility
Beyond established risks like cardiovascular disease and hypertension, the study identified several less-established factors associated with testing positive for COVID-19:
- Dementia and Alzheimer’s: These were among the strongest predictors of susceptibility, with dementia carrying an odds ratio (OR) of 5.2 and Alzheimer’s an OR of 7.7, even after controlling for age.
- Mental Health Conditions: Depression (OR 2.1) and anxiety (OR 1.7) were significantly associated with a higher risk of infection. The authors suggest this may be due to barriers in accessing care or a diminished capacity for personal protective measures.
- Vitamin D Deficiency: This was associated with an increased risk of susceptibility (OR 1.8).
Predictors of Hospitalization and Severity
While respiratory health is often the primary focus of COVID-19 research, this study found that renal health was the predominant premorbid risk factor for hospital admission. Patients with a history of renal transplant faced a staggering risk (OR 9.7). Other significant predictors for admission included disorders of the immune system (OR 6.0) and a history of sepsis (OR 8.4).
The Role of Medications
The study provided critical insights into how common medications interact with COVID-19 risk:
- The Steroid Paradox: Patients previously prescribed oral steroids were 39% less likely to test positive (OR 0.61). However, if they did contract the virus, they were 4.5 times more likely to be hospitalized. This suggests that steroids might mask early symptoms, leading to delayed testing until the disease has reached an advanced stage.
- ACE Inhibitors and ARBs: Despite early pandemic concerns that these common blood pressure medications might facilitate viral entry, the study found no evidence that they increased the risk of infection, admission, or severe outcomes.
Limitations and Future Directions
The study's primary limitation is the lack of detailed socioeconomic status (SES) indicators within the EHR, which likely account for much of the observed ethnic disparities. Additionally, hospitalization and ICU admission are subject to clinician judgment; for instance, a physician might admit a transplant patient more readily due to perceived vulnerability.
Finally, the researchers identified "outlier" patients—young, healthy individuals who nevertheless developed severe disease. These cases represent a priority for future genetic research to identify rare immunological vulnerabilities to SARS-CoV-2. Understanding these diverse risk factors is essential for shaping government policy, guiding clinical decisions, and prioritizing future research in the ongoing effort to manage COVID-19.
Summary updated